Liquid bendamustine pharmaceutical compositions
AssigneeHospira Australia Pty Ltd.
InventorsAndrew Malcolm Knill, Noel Norris
Life of this patent
Estimating the term…
Loading patent…
AssigneeHospira Australia Pty Ltd.
InventorsAndrew Malcolm Knill, Noel Norris
Estimating the term…
Concentrated liquid pharmaceutical compositions comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) at least about 2% water, suitable, after dilution, for administration to a mammal by injection are provided. The concentrated liquid pharmaceutical compositions can comprise a non-aqueous solvent comprising at least one organic polymeric compound solvent and at least one organic small molecule solvent. Methods of treating a cancer in a mammal in need of such treatment comprising administering to the mammal an effective amount of a concentrated liquid bendamustine pharmaceutical composition of the invention are also provided.
A concentrated liquid pharmaceutical composition comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) at least about 2% water v/v of the composition, wherein the pharmaceutical composition is, after dilution, suitable for administration to a mammal by injection.
A concentrated liquid pharmaceutical composition comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) from about 2% to about 30% water v/v of the composition, wherein the pharmaceutical composition is, after dilution, suitable for administration to a mammal.
A method for preparing a concentrated liquid pharmaceutical composition, which method comprises combining:
A method for preparing a concentrated liquid bendamustine pharmaceutical composition, which method comprises 1) combining:
A concentrated liquid pharmaceutical composition comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) from about 82% to about 98% of a non-aqueous solvent v/v of the composition, and c) from about 2% to about 18% water v/v of the composition, wherein the pharmaceutical composition is, after dilution, suitable for administration to a mammal.
Dependencies are inferred from the claim text.